Effect of Lactobacillus rhamnosus HN001 in Pregnancy on Postpartum Symptoms of Depression and Anxiety: A Randomised Double-blind Placebo-controlled Trial

R F Slykerman, F Hood, K Wickens, J M D Thompson, C Barthow, R Murphy, J Kang, J Rowden, P Stone, J Crane, T Stanley, P Abels, G Purdie, R Maude, E A Mitchell, Probiotic in Pregnancy Study Group, R F Slykerman, F Hood, K Wickens, J M D Thompson, C Barthow, R Murphy, J Kang, J Rowden, P Stone, J Crane, T Stanley, P Abels, G Purdie, R Maude, E A Mitchell, Probiotic in Pregnancy Study Group

Abstract

Background: Probiotics may help to prevent symptoms of anxiety and depression through several putative mechanisms.

Objective: The aim of this study was to evaluate the effect of Lactobacillus rhamnosus HN001 (HN001) given in pregnancy and postpartum on symptoms of maternal depression and anxiety in the postpartum period. This was a secondary outcome, the primary outcome being eczema in the offspring at 12months of age.

Design, setting, participants: A randomised, double-blind, placebo-controlled trial of the effect of HN001 on postnatal mood was conducted in 423 women in Auckland and Wellington, New Zealand. Women were recruited at 14-16weeks gestation.

Intervention: Women were randomised to receive either placebo or HN001 daily from enrolment until 6months postpartum if breastfeeding.

Outcome measures: Modified versions of the Edinburgh Postnatal Depression Scale and State Trait Anxiety Inventory were used to assess symptoms of depression and anxiety postpartum.

Trial registration: Australia NZ Clinical Trials Registry: ACTRN12612000196842.

Findings: 423 women were recruited between December 2012 and November 2014. 212 women were randomised to HN001 and 211 to placebo. 380 women (89.8%) completed the questionnaire on psychological outcomes, 193 (91.0%) in the treatment group and 187 (88.6%) in the placebo group. Mothers in the probiotic treatment group reported significantly lower depression scores (HN001 mean=7·7 (SD=5·4), placebo 9·0 (6·0); effect size -1·2, (95% CI -2·3, -0·1), p=0·037) and anxiety scores (HN001 12·0 (4·0), placebo 13·0 (4·0); effect size -1·0 (-1·9, -0·2), p=0·014) than those in the placebo group. Rates of clinically relevant anxiety on screening (score>15) were significantly lower in the HN001 treated mothers (OR=0·44 (0·26, 0·73), p=0·002).

Interpretation: Women who received HN001 had significantly lower depression and anxiety scores in the postpartum period. This probiotic may be useful for the prevention or treatment of symptoms of depression and anxiety postpartum.

Funding source: Health Research Council of New Zealand (11/318) and Fonterra Co-operative Group Ltd.

Keywords: Anxiety; Depression; Microbiome-gut-brain axis; Probiotic; Randomised controlled trial.

Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Figures

Fig. 1
Fig. 1
Participant flow showing the numbers of participants who were randomly assigned, received intended treatment and were analysed for the psychological outcomes.

References

    1. Abbott M.W., Williams M.M. Postnatal depressive symptoms among Pacific mothers in Auckland: prevalence and risk factors. Aust. N. Z. J. Psychiatry. 2006;40:230–238.
    1. Akkasheh G., Kashani-Poor Z., Tajabadi-Ebrahimi M. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. Nutrition. 2016;32:315–320.
    1. Barrera-Bugueño C., Realini O., Escobar-Luna J., Sotomayor-Zarate R., Gotteland M., Julio-Pieper M., Bravo J.A. Anxiogenic effects of a lactobacillus, inulin and the synbiotic on healthy juvenile rats. Neuroscience. 2017;359:18–29.
    1. Barthow C., Wickens K., Stanley T. The Probiotics in Pregnancy Study (PIP Study): rationale and design of a double-blind randomised controlled trial to improve maternal health during pregnancy and prevent infant eczema and allergy. BMC Pregnancy Childbirth. 2016;16:133.
    1. Battle C.L., Salisbury A.L., Schofield C.A., Ortiz-Hernandez S. Perinatal antidepressant use: understanding women's preferences and concerns. J. Psychiatr. Pract. 2003;19:443–453.
    1. Bravo J.A., Forsythe P., Chew M.V. Ingestion of Lactobacillus strain regulates emotional behaviour and central GABA receptor expression in a mouse via the vagus nerve. PNAS. 2011;108:16050–16059.
    1. Carabotti M., Scirocco A., Maselli M.A., Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann. Gastroenterol. 2015;28:203–209.
    1. Cepeda M.S., Katz E.G., Blacketer C. Microbiome-gut-brain axis: probiotics and their association with depression. J. Neuropsychiatr. Clin. Neurosci. 2017 Winter;29(1):39–44.
    1. Collins S.M., Kassam Z., Bercik P. The adoptive transfer of behavioral phenotype via the intestinal microbiota: experimental evidence and clinical implications. Curr. Opin. Microbiol. 2013;16:240–245.
    1. Cox J.L., Holden J.M., Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br. J. Psychiatry. 1987;150(6):782.
    1. Da Costa D., Dritsa M., Rippen N., Lowensteyn Khalife S. Health-related quality of life in postpartum depressed women. Arch. Women's Ment. Health. 2006;9:95–102.
    1. Dapoigny M., Piche T., Ducrote P., Lundard B., Cardot J., Bernalier-Donadille A. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized double-blind study. World J. Gastroenterol. 2012;18:2067–2075.
    1. Dawson S.L., Dash S.R., Jacka F.N. The importance of diet and gut health to the treatment and prevention of mental disorders. Int. Rev. Neurobiol. 2016;131:325–346.
    1. Dekker J.W., Wickens K., Black P.N. Safety aspects of probiotic bacterial strains Lactobacillus rhamnosus HN001 and Bifidobacterium animalis subps. lactis HN019 in human infants aged 0 to 2 years. Int. Dairy J. 2009;19:149–154.
    1. Desbonnet L., Garrett L., Clarke G., Kiely B., Cryan J.F., Dinan T.G. Effect of the probiotic Bifidobacterium Infantis in the maternal separation model of depression. Neuroscience. 2010;170:1179–1188.
    1. Dickerson F.B., Stallings C., Origoni A. Effects of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomised, placebo-controlled trial. Prim. Care Companion CNS Disord. 2014;16:1.
    1. Dinan T.G., Cryan J.F. The impact of gut microbiota on brain and behavior: implications for psychiatry. Curr. Opin. Clin. Nutr. Metab. Care. 2015;18:552–558.
    1. Dinan T.G., Cryan J.F. Mood by microbes: towards clinical translation. Genome Med. 2016;6:36–38.
    1. Gartlehner G., Hansen R.A., Carey T.S., Lohr K.N., Gaynes B.N., Randolph L.C. Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis. Int. Clin. Psychopharmacol. 2005;20(2):59–69.
    1. Grace S.L., Evindar A., Stewart D.E. The effect of postpartum depression on child cognitive development and behavior: a review and critical analysis of the literature. Arch. Women's Ment. Health. 2003;6:263–274.
    1. Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H., Salminen S., Calder P.C., Sanders M.E. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014;11(8):506–514.
    1. Jacka F.N., O'Neil A., Opie R., Itsiopoulos C., Cotton S., Mohebbi M., Castle D., Dash S., Mihalopoulos C., Chatterton M.L., Brazionis L., Dean O.M., Hodge A.M., Berk M. A randomised controlled trial of dietary improvement for adults with major depression (the ‘SMILES’ trial) BMC Med. 2017;15(1):23.
    1. Kelly J.R., Allen A.P., Temko A., Hutch W., Kennedy P.J., Farid N., Murphy E., Boylan G., Bienenstock J., Cryan J.F., Clarke G., Dinan T.G. Lost in translation? The potential psychobiotic lactobacillus rhamnosus (JB-1) fails to modulate stress or cognitive performance in healthy male subjects. Brain Behav. Immun. 2017;61:50–59. Mar.
    1. Kristensen N.B., Bryrup T., Allin K.H., Nielsen T., Hansen T.H., Pedersen O. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Med. 2016;8:52.
    1. Lai J.S., Hiles S., Bisquera A., Hure A.J., McEvoy M., Attia J. A systematic review and meta-analysis of dietary patterns and depression in community-dwelling adults. Am. J. Clin. Nutr. 2013;99(1):181–197.
    1. Li L., Su Q., Xie B., Duan L., Zhao W., Hu D., Wu R., Liu H. Gut microbes in correlation with mood: case study in a closed experimental human life support system. Neurogastroenterol. Motil. 2016 Aug;28(8):1233–1240.
    1. Logan A.C., Katzman M. Major depressive disorder: probiotics may be an adjuvant therapy. Med. Hypotheses. 2005;64(3):533–538.
    1. Marteau T.M., Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI) Br. J. Clin. Psychol. 1992;31:301–306.
    1. Mayer E.A., Knight R., Mazmanian S.K., Cryan J.F., Tillisch K. Gut microbes and the brain: paradigm shift in neuroscience. J. Neurosci. 2014;34(46):15490–15496.
    1. Mi G., Zhao L., Qiao D., Kang W., Tang M., Xu J. Effectiveness of Lactobacillus reuteri in infantile colic and colicky induced maternal depression: a prospective single blind randomized trial. Antonie Van Leeuwenhoek. 2015;107:154–155.
    1. PMMRC . Health Quality & Safety Commission; Wellington: 2014. Eighth Annual Report of the Perinatal and Maternal Mortality Review Committee: Reporting Mortality 2012.
    1. Rao A.V., Bested A.C., Beaulne T.M. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog. 2009;1(1):6.
    1. Reale M., Boscolo P., Bellante V. Daily intake of Lactobacillus casei Shirota increases natural killer cell activity in smokers. Br. J. Nutr. 2012;108:308–314.
    1. Romijn A.R., Rucklidge J.J. Systematic review of evidence to support the theory of psychobiotics. Nutr. Rev. 2015;73:675–693.
    1. Romijn A.R., Rucklidge J.J., Kuijer R.G., Frampton C. A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression. Aust. N. Z. J. Psychiatry. 2017 published online January 2017.
    1. Sanchez M., Darimont C., Panahi S., Drapeau V., Marette A., Taylor V.H., Doré J., Tremblay A. Effects of a diet-based weight-reducing program with probiotic supplementation on satiety efficiency, eating behaviour traits, and psychosocial behaviours in obese individuals. Nutrients. 2017;9(3):284.
    1. Scott K.M., Von Korff M., Ormel J., Zhang M.Y., Bruffaerts R., Alonso J., Kessler R.C., Tachimori H., Karam E., Levinson D., Bromet E.J., Posada-Villa J., Gasquet I., Angermeyer M.C., Borges G., de Girolamo G., Herman A., Haro J.M. Mental disorders among adults with asthma: results from the World Mental Health Survey. Gen. Hosp. Psychiatry. 2007;29:123–133.
    1. Selhub E.M., Logan A.C., ACl Bested. Fermented foods, microbiota, and mental health: ancient practice meets nutritional psychiatry. J. Physiol. Anthropol. 2014;33:2. Jan 15.
    1. Tronick E., Reck C. Infants of depressed mothers. Harvard Rev. Psychiatry. 2009;17:147–156.
    1. Wallace C.J.K., Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. Ann. General Psychiatry. 2017;16:14.
    1. Wang Y., Kasper L.H. The role of microbiome in central nervous system disorders. Brain Behav. Immun. 2014;38:1–12.
    1. Webster M.L., Thompson J.M., Mitchell E.A., Werry J.S. Postnatal depression in a community cohort. Aust. N. Z. J. Psychiatry. 1994;28(1):42–49.
    1. Wickens K., Black P.N., Stanley T.V. A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. J. Allergy Clin. Imunol. 2008;122:788–794.
    1. Wickens K., Black P., Stanley T.V. A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years. Clin. Exp. Allergy. 2012;42:1071–1079.
    1. Wickens K., Stanley T.V., Mitchell E.A. Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization? Clin. Exp. Allergy. 2013;43:1048–1057.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する